Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Dow
Colorcon
Johnson and Johnson
Merck

Last Updated: January 24, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Serelaxin


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Serelaxin?

Serelaxin is an investigational drug.

There have been 14 clinical trials for Serelaxin. The most recent clinical trial was a Phase 3 trial, which was initiated on October 2nd 2013.

The most common disease conditions in clinical trials are Heart Failure, Liver Cirrhosis, and Hypertension, Portal. The leading clinical trial sponsors are Novartis Pharmaceuticals, Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies, and NHS Lothian.

There are thirty-two US patents protecting this investigational drug and seven hundred and forty-two international patents.

Recent Clinical Trials for Serelaxin
TitleSponsorPhase
Serelaxin To Lower Portal PressureNHS LothianPhase 2
Serelaxin To Lower Portal PressureNovartis PharmaceuticalsPhase 2
Serelaxin To Lower Portal PressureUniversity of EdinburghPhase 2

See all Serelaxin clinical trials

Clinical Trial Summary for Serelaxin

Top disease conditions for Serelaxin
Top clinical trial sponsors for Serelaxin

See all Serelaxin clinical trials

US Patents for Serelaxin

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Serelaxin ⤷  Sign up for a Free Trial ANP fragment adjuvant therapy to standard of care (SOC) diuretic treatment Madeleine Pharmaceuticals Pty Ltd. (Mount Barker, AU) ⤷  Sign up for a Free Trial
Serelaxin ⤷  Sign up for a Free Trial sGC stimulators Ironwood Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Sign up for a Free Trial
Serelaxin ⤷  Sign up for a Free Trial Modified relaxin B chain peptides THE FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH (Parkville, Victoria, AU) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Serelaxin

Drugname Country Document Number Estimated Expiration Related US Patent
Serelaxin Australia AU2015230666 2034-04-09 ⤷  Sign up for a Free Trial
Serelaxin Australia AU2015230778 2034-04-09 ⤷  Sign up for a Free Trial
Serelaxin European Patent Office EP2968458 2033-03-15 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Dow
Colorcon
Johnson and Johnson
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.